"Glucuronosyltransferase" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A family of enzymes accepting a wide range of substrates, including phenols, alcohols, amines, and fatty acids. They function as drug-metabolizing enzymes that catalyze the conjugation of UDPglucuronic acid to a variety of endogenous and exogenous compounds. EC 2.4.1.17.
| Descriptor ID |
D014453
|
| MeSH Number(s) |
D08.811.913.400.450.480
|
| Concept/Terms |
Glucuronosyltransferase- Glucuronosyltransferase
- Glucuronyltransferase
- UDP Glucuronyl Transferase
- Glucuronyl Transferase, UDP
- Transferase, UDP Glucuronyl
- Glucuronic Transferase
- Transferase, Glucuronic
- UDP Glucuronosyltransferase
- Glucuronosyltransferase, UDP
7-Hydroxycoumarin UDP Glucuronyltransferase- 7-Hydroxycoumarin UDP Glucuronyltransferase
- 7 Hydroxycoumarin UDP Glucuronyltransferase
- Glucuronyltransferase, 7-Hydroxycoumarin UDP
- UDP Glucuronyltransferase, 7-Hydroxycoumarin
|
Below are MeSH descriptors whose meaning is more general than "Glucuronosyltransferase".
Below are MeSH descriptors whose meaning is more specific than "Glucuronosyltransferase".
This graph shows the total number of publications written about "Glucuronosyltransferase" by people in this website by year, and whether "Glucuronosyltransferase" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2000 | 0 | 1 | 1 |
| 2004 | 1 | 0 | 1 |
| 2007 | 1 | 0 | 1 |
| 2009 | 0 | 2 | 2 |
| 2013 | 1 | 0 | 1 |
| 2017 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Glucuronosyltransferase" by people in Profiles.
-
Ocean AJ, Starodub AN, Bardia A, Vahdat LT, Isakoff SJ, Guarino M, Messersmith WA, Picozzi VJ, Mayer IA, Wegener WA, Maliakal P, Govindan SV, Sharkey RM, Goldenberg DM. Sacituzumab govitecan (IMMU-132), an anti-Trop-2-SN-38 antibody-drug conjugate for the treatment of diverse epithelial cancers: Safety and pharmacokinetics. Cancer. 2017 Oct 01; 123(19):3843-3854.
-
Goetz MP, McKean HA, Reid JM, Mandrekar SJ, Tan AD, Kuffel MA, Safgren SL, McGovern RM, Goldberg RM, Grothey AA, McWilliams R, Erlichman C, Ames MM. UGT1A1 genotype-guided phase I study of irinotecan, oxaliplatin, and capecitabine. Invest New Drugs. 2013 Dec; 31(6):1559-67.
-
Sperling MR, Greenspan A, Cramer JA, Kwan P, K?lvi?inen R, Halford JJ, Schmitt J, Yuen E, Cook T, Haas M, Novak G. Carisbamate as adjunctive treatment of partial onset seizures in adults in two randomized, placebo-controlled trials. Epilepsia. 2010 Mar; 51(3):333-43.
-
Argiris A, Buchanan A, Brockstein B, Kolesar J, Ghebremichael M, Pins M, Hahn K, Axelrod R, Forastiere A. Docetaxel and irinotecan in recurrent or metastatic head and neck cancer: a phase 2 trial of the Eastern Cooperative Oncology Group. Cancer. 2009 Oct 01; 115(19):4504-13.
-
Hoskins JM, Goldberg RM, Qu P, Ibrahim JG, McLeod HL. UGT1A1*28 genotype and irinotecan-induced neutropenia: dose matters. J Natl Cancer Inst. 2007 Sep 05; 99(17):1290-5.
-
Zhang D, Zhao W, Roongta VA, Mitroka JG, Klunk LJ, Zhu M. Amide N-glucuronidation of MaxiPost catalyzed by UDP-glucuronosyltransferase 2B7 in humans. Drug Metab Dispos. 2004 May; 32(5):545-51.
-
Sauter BV, Parashar B, Chowdhury NR, Kadakol A, Ilan Y, Singh H, Milano J, Strayer DS, Chowdhury JR. A replication-deficient rSV40 mediates liver-directed gene transfer and a long-term amelioration of jaundice in gunn rats. Gastroenterology. 2000 Nov; 119(5):1348-57.